BSE Live
Mar 19, 16:01Prev. Close
381.90
Open Price
380.75
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 19, 15:55Prev. Close
382.25
Open Price
376.55
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
366.10 (300)
| Key Financial Ratios of SMS Pharmaceuticals (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 2.39 | 6.29 | 27.15 | 20.96 | 20.75 | |
| Diluted EPS (Rs.) | 2.39 | 6.29 | 27.15 | 20.96 | 20.75 | |
| Cash EPS (Rs.) | 18.34 | 20.11 | 38.89 | 28.90 | 38.10 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 213.08 | 211.85 | 208.16 | 182.71 | 135.67 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 213.08 | 211.85 | 208.16 | 182.71 | 135.67 | |
| Dividend / Share(Rs.) | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | |
| Revenue from Operations/Share (Rs.) | 222.58 | 249.69 | 237.04 | 172.50 | 299.87 | |
| PBDIT/Share (Rs.) | 22.72 | 21.10 | 43.22 | 43.30 | 55.81 | |
| PBIT/Share (Rs.) | 14.37 | 14.83 | 38.05 | 39.13 | 45.08 | |
| PBT/Share (Rs.) | 2.88 | 7.93 | 32.37 | 32.66 | 31.95 | |
| Net Profit/Share (Rs.) | 2.39 | 6.29 | 27.15 | 20.96 | 20.75 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 10.20 | 8.44 | 18.23 | 25.10 | 18.61 | |
| PBIT Margin (%) | 6.45 | 5.93 | 16.05 | 22.68 | 15.03 | |
| PBT Margin (%) | 1.29 | 3.17 | 13.65 | 18.93 | 10.65 | |
| Net Profit Margin (%) | 1.07 | 2.51 | 11.45 | 12.15 | 6.91 | |
| Return on Networth / Equity (%) | 1.12 | 2.96 | 13.04 | 11.47 | 15.29 | |
| Return on Capital Employed (%) | 0.72 | 1.93 | 9.63 | 8.97 | 7.95 | |
| Return on Assets (%) | 0.55 | 1.54 | 7.69 | 7.05 | 5.12 | |
| Total Debt/Equity (X) | 0.77 | 0.65 | 0.44 | 0.34 | 1.18 | |
| Asset Turnover Ratio (%) | 51.21 | 61.45 | 67.16 | 58.07 | 74.01 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.58 | 2.09 | 2.46 | 3.34 | 1.61 | |
| Quick Ratio (X) | 0.86 | 1.21 | 1.57 | 2.72 | 1.16 | |
| Inventory Turnover Ratio (X) | 2.94 | 3.48 | 3.73 | 4.38 | 4.62 | |
| Dividend Payout Ratio (NP) (%) | 41.81 | 31.80 | 7.37 | 9.54 | 9.63 | |
| Dividend Payout Ratio (CP) (%) | 5.45 | 9.94 | 5.14 | 6.91 | 5.24 | |
| Earnings Retention Ratio (%) | 58.19 | 68.20 | 92.63 | 90.46 | 90.37 | |
| Cash Earnings Retention Ratio (%) | 94.55 | 90.06 | 94.86 | 93.09 | 94.76 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 320.36 | 194.19 | 234.40 | 247.69 | 0.00 | |
| EV/Net Operating Revenue (X) | 1.44 | 0.78 | 0.99 | 1.44 | 0.00 | |
| EV/EBITDA (X) | 14.08 | 9.19 | 5.42 | 5.72 | 0.00 | |
| MarketCap/Net Operating Revenue (X) | 0.73 | 0.31 | 0.70 | 1.63 | 0.00 | |
| Retention Ratios (%) | 58.18 | 68.19 | 92.62 | 90.45 | 90.36 | |
| Price/BV (X) | 0.76 | 0.36 | 0.80 | 1.54 | 0.00 | |
| Price/Net Operating Revenue | 0.73 | 0.31 | 0.70 | 1.63 | 0.00 | |
| Earnings Yield | 0.01 | 0.08 | 0.16 | 0.07 | 0.00 |
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
09.02.2026
05.01.2026
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
14.11.2025
SMS Pharma Consolidated September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
12.11.2025
SMS Pharma Standalone September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
19.03.2026
19.03.2026
18.03.2026
18.03.2026
MFs boost healthcare exposure, turn overweight on earnings recovery and valuations
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth